GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults

Phase 1

Completed

Conditions: Virus Diseases

Interventions: Biological: 1 µg CoV2 SAM (LNP)

First Posted Date: 2021-02-17

Last Posted Date: 2024-01-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 40

Registration Number: NCT04758962

Locations: 🇺🇸
GSK Investigational Site, Rochester, New York, United States

Sun Protection Factor (SPF) Determination of Two Sunscreen-Containing Lip Balms

Not Applicable

Completed

Conditions: Sunscreening Agents

Interventions: Drug: ChapStick Moisturizer, Classic Flavor
Drug: ChapStick Moisturizer, Strawberry Flavor

First Posted Date: 2021-02-11

Last Posted Date: 2022-03-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 14

Registration Number: NCT04749459

Locations: 🇺🇸
GSK Investigational Site, Fairfield, New Jersey, United States

A Proof-of-principle Clinical Study Investigating the Efficacy of an Experimental Dentifrice Containing Sodium Bicarbonate and Sodium Hyaluronate on Gingivitis

Phase 2

Completed

Conditions: Gingivitis

Interventions: Other: Positive control dentifrice
Other: Negative control dentifrice
Other: Experimental Dentrifrice

First Posted Date: 2021-02-04

Last Posted Date: 2024-01-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 110

Registration Number: NCT04737538

Locations: 🇨🇦
GSK Investigational Site, Mississauga, Ontario, Canada

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Phase 3

Active, not recruiting

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSVPreF3 OA investigational vaccine

First Posted Date: 2021-02-01

Last Posted Date: 2023-12-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1720

Registration Number: NCT04732871

Locations: 🇨🇳
GSK Investigational Site, Taoyuan County, Taiwan

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Phase 3

Active, not recruiting

Conditions: Asthma

Interventions: Biological: GSK3511294 (Depemokimab)
Biological: Mepolizumab
Biological: Benralizumab
Biological: Placebo
Drug: Standard of care (SoC)
Device: Pre-filled Syringes (PFS)